What question did this study set out to answer?

To investigate if treatment response to combined dopaminergic and anticholinergic therapy varies by genotype in pediatric genetic dystonia.

May 15, 2026Brain and DevelopmentOpen Access

Genotype-dependent response to combined levodopa/benserazide and trihexyphenidyl in pediatric genetic dystonia

View Full Paper

Ask AI

Bookmark

To investigate if treatment response to combined dopaminergic and anticholinergic therapy varies by genotype in pediatric genetic dystonia.
Retrospective cohort study of 36 children with genetically confirmed dystonia.
Participants divided into three subgroups based on genotype: PANK2, channelopathies, and other monogenic etiologies.
All received 16 weeks of levodopa/benserazide and trihexyphenidyl; outcomes measured included BADS, GMFM-88, QUEST, and CP-QOL.
PANK2 patients showed excellent improvement (ΔBADS -6.6 ± 3.0; ΔGMFM-88 + 49.6 ± 45.8).
Other monogenic patients showed moderate improvement (ΔBADS -6.1 ± 1.9; ΔGMFM-88 + 32.2 ± 26.5).
Channelopathy patients had minimal benefit (ΔBADS -3.5 ± 1.2; ΔGMFM-88 + 6.2 ± 2.9; p < 0.001 compared to other groups).

No takes yet. Share an insight, caveat, or question.

Retrospective cohort study finds genotype impacts treatment response in pediatric dystonia, suggesting personalized therapy approaches.

Zhou et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark